文献速递肺结节与肺癌慢阻肺

肺癌筛查实施:复杂性与优先事项

Lung cancer screening implementation: Complexities and priorities.
PubMed 文献 · Respirology · 2020-01-01

本文为综述,指出两项标志性试验使用低剂量CT(LDCT)已证实肺癌筛查可降低死亡率并发现早期病变,美国与韩国已实施筛查。文章围绕患者旅程讨论筛查风险阈值选择、吸烟者招募与筛查依从性、肺结节标准化管理、戒烟整合及项目质控等实施要点。

要点

  • LDCT筛查降低肺癌死亡率与发现早期病变已获两项标志性试验证实
  • 吸烟相关污名影响吸烟者参与筛查,需针对性招募策略
  • 肺结节管理应标准化并整合概率风险评估与纵向体积分析

核心结论

  • 基于两项标志性试验结果,LDCT肺癌筛查降低死亡率与检测早期疾病的获益已无疑问,但需谨慎实施与多方协调以优化获益并减少危害。

研究设计与样本

  • 综述,围绕患者旅程讨论肺癌筛查实施的关键环节,包括筛查风险阈值选择、目标人群招募、筛查依从性及项目实施要素。

主要发现

  • 美国与韩国已实施肺癌筛查,其他地区正在考虑;肺癌风险由吸烟驱动,吸烟者因污名等因素通常「难以触达」,影响其参与筛查。
  • 综述回顾了试验与真实世界项目的招募策略及相应筛查依从性,并建议采用标准化命名记录与计算招募结局以便跨研究比较。

关键数值与推荐

  • 提出需采用标准化、多学科的肺结节管理方法,纳入概率性结节风险评估与纵向体积分析,以减少不必要的下游检查与手术;并整合戒烟及对其他烟草相关疾病(如冠状动脉钙化与慢阻肺)的识别与干预。

临床怎么用

  • 需采取全项目方法:国家支持并与烟草控制规划整合,配备适当资金、认证、数据收集、质量保证与报告机制,以减少机会性、临时性筛查的风险。

局限性

  • 实施方面可能因不同医疗环境而异,且仍存在重要知识空白,需进一步研究以优化筛查获益并减少危害;实施研究需在 informing 靶向LDCT筛查政策方面发挥更大作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lung cancer is the number one cause of cancer death worldwide. The benefits of lung cancer screening to reduce mortality and detect early-stage disease are no longer in any doubt based on the results of two landmark trials using LDCT. Lung cancer screening has been implemented in the US and South Korea and is under consideration by other communities. Successful translation of demonstrated research outcomes into the routine clinical setting requires careful implementation and co-ordinated input from multiple stakeholders. Implementation aspects may be specific to different healthcare settings. Important knowledge gaps remain, which must be addressed in order to optimize screening benefits and minimize screening harms. Lung cancer screening differs from all other cancer screening programmes as lung cancer risk is driven by smoking, a highly stigmatized behaviour. Stigma, along with other factors, can impact smokers' engagement with screening, meaning that smokers are generally 'hard to reach'. This review considers critical points along the patient journey. The first steps include selecting a risk threshold at which to screen, successfully engaging the target population and maximizing screening uptake. We review barriers to smoker engagement in lung and other cancer screening programmes. Recruitment strategies used in trials and real-world (clinical) programmes and associated screening uptake are reviewed. To aid cross-study comparisons, we propose a standardized nomenclature for recording and calculating recruitment outcomes. Once participants have engaged with the screening programme, we discuss programme components that are critical to maximize net benefit. A whole-of-programme approach is required including a standardized and multidisciplinary approach to pulmonary nodule management, incorporating probabilistic nodule risk assessment and longitudinal volumetric analysis, to reduce unnecessary downstream investigations and surgery; the integration of smoking cessation; and identification and intervention for other tobacco related diseases, such as coronary artery calcification and chronic obstructive pulmonary disease. National support, integrated with tobacco control programmes, and with appropriate funding, accreditation, data collection, quality assurance and reporting mechanisms will enhance lung cancer screening programme success and reduce the risks associated with opportunistic, ad hoc screening. Finally, implementation research must play a greater role in informing policy change about targeted LDCT screening programmes.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Rankin NM, McWilliams A, Marshall HM, et al. Lung cancer screening implementation: Complexities and priorities. Respirology. 2020. PMID: 33200529. doi:10.1111/resp.13963

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。